| OTC product revenue | |
| Medical device revenue | |
| Total revenues | |
| Cost of sales | |
| Gross profit | |
| Research and development | 2.46M |
| General and administrative | 3.32M |
| Amortization | |
| Total operating loss | -5.78M |
| Gain on sale of fixed assets | |
| Loss on extinguishment of debt | |
| Investment income | 318 |
| Gain on change in fair value of warrant liability | 336.65K |
| Net interest expense | |
| Net loss | -5.88M |
| Dividends on preferred stock | |
| Net loss applicable to common shareholders | -8.86M |
| Basic and diluted loss per common share | |
| Weighted average number of common shares outstanding - basic and diluted | |